A Crossover Study of the Acute Effects of Olanzapine in Healthy Volunteers

Penn State Health

Status

Completed

Conditions

Diabetes Mellitus

Insulin Resistance

Treatments

Drug: Olanzapine 10 mg po qhs for 3 days

Drug: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT00741026

28230

Details and patient eligibility

About

The purpose of this clinical research study is to examine the acute hormonal and metabolic effects of the drug olanzapine, as well as appetite effects, in healthy volunteers. The hypotheses to be tested are that: (1) Olanzapine rapidly attenuates plasma leptin and (2) rapidly alters glucose tolerance in healthy volunteers. These questions will be answered by having volunteers undergo two glucose tolerance tests in a crossover study design.

Enrollment

15 patients

Sex

All

Ages

18 to 30 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy Volunteer
Body Mass Index of 18.5-25 kilograms per square meter
Must be able to swallow tablets
Able to give informed consent

Exclusion criteria

Any DSM-IV TR Axis I psychiatric disorder (except nicotine dependence)
Presence of any medical disorder that may confound the assessment of relevant biologic measures, including: significant organ system dysfunction, metabolic diseases, type 1 diabetes mellitus, type 2 diabetes mellitus, pregnancy, endocrine disease, coagulopathy, clinically significant anemia, or acute infection
Subjects who have taken any antipsychotic medication within the last 6 months
Personal or family history of seizures and/or cardiac arrhythmias